July 27, 2018 10:14 AM EDT

After huge mega-round, CStone poaches Goldman's Richard Yeh as CFO; Both Hooper and Harper exit Amgen's revolving door

Amber Tong

→ Weeks after closing its star-studded $260 million Series B round, CStone Pharmaceuticals has poached Goldman Sachs director Richard Yeh to manage all of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After huge mega-round, CStone poaches Goldman's Richard Yeh as CFO; Both Hooper and Harper exit Amgen's revolving door

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Af­ter huge mega-round, CStone poach­es Gold­man's Richard Yeh as CFO; Both Hoop­er and Harp­er ex­it Am­gen's re­volv­ing door

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

After huge mega-round, CStone poaches Goldman's Richard Yeh as CFO; Both Hooper and Harper exit Amgen's revolving door

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role